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Objective: To investigate whether low-density granulocytes (LDGs) are an
immunophenotypic feature of patients with multiple sclerosis (MS) or neuromyelitis
optica spectrum disorder (NMOSD).
Methods: Blood samples were collected from 20 patients with NMOSD and 17 patients
with MS, as well as from 15 patients with Systemic Lupus Erythematosus (SLE) and
23 Healthy Donors (HD). We isolated peripheral blood mononuclear cells (PBMCs)
with density gradient separation and stained the cells with antibodies against CD14,
CD15, CD16, and CD45, and analyzed the cells by flow cytometry or imaging flow
cytometry.We defined LDGs as CD14−CD15high and calculated their share in total PBMC
leukocytes (CD45+) as well as the share of CD16hi LDGs. Clinical data on disease course,
medication, and antibody status were obtained.
Results: LDGs were significantly more common in MS and NMOSD than in HDs,
comparable to SLE samples (median values HD 0.2%, MS 0.9%, NMOSD 2.1%,
SLE 4.3%). 0/23 of the HDs, but 17/20 NMOSD and 11/17MS samples as well as
13/15 SLE samples had at least 0.7 % LDGs. NMOSD patients without continuous
immunosuppressive treatment had significantly more LDGs compared to their treated
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counterparts. LDG nuclear morphology ranged from segmented to rounded, suggesting
a heterogeneity within the group.
Conclusion: LDGs are a feature of the immunophenotype in some patients with MS
and NMOSD.
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INTRODUCTION
Low-Density Granulocytes (LDGs) are neutrophilic granulocytes
that remain in the fraction of peripheral blood mononuclear cells
(PBMC) after density gradient separation. When first described,
they were noted to be a feature of rheumatologic diseases such
as Systemic Lupus Erythematosus (SLE) (1), while more recent
works described LDGs in various conditions such as asthma (2),
tuberculosis (3), and psoriasis (4). LDGs have been implicated
in the pathogenesis of SLE by producing type I interferons
and undergoing spontaneous NETosis (generation of Neutrophil
extracellular traps), thus providing potentially immunogenic
nuclear matter (5, 6). Their role in the pathogenesis of other
diseases is less clear.
The origin of the LDGs has not yet been elucidated and it
has been proposed that they represent immature or degranulated
neutrophils. Interestingly, LDGs in SLE display an immature
nuclear structure even though they express the surface markers
of mature granulocytes, such as CD16 (5, 6).
Neuromyelitis Optica Spectrum Disorder (NMOSD) and
Multiple Sclerosis (MS) are neuroinflammatory conditions
of unknown etiology. The evidence for the involvement of
granulocytes in the pathogenesis of MS has been scarce so far,
while some early studies indicate a role of neutrophils in NMOSD
pathogenesis (7, 8).
In this study, we provide the first evidence for the existence
of LDGs in MS and NMOSD and thus add another puzzle piece
to the role of the innate immune system in the pathogenesis of
these diseases.
MATERIALS AND METHODS
SLE patients were recruited from the rheumatologic outpatient
departments at Charité Universitätsmedizin Berlin. Data
on MS- and NMOSD-patients were derived from ongoing
observational studies at the NeuroCure Clinical Research
Center, Charité—Universitätsmedizin Berlin without prior
selection according to sex, age, or other clinical parameters.
These studies were approved by the ethics committee of
the Charité—Universitätsmedizin Berlin (MS: EA1/163/12;
NMOSD: EA1/041/14) and conducted according to the 1964
Declaration of Helsinki in its currently applicable version.
Written, informed consent was obtained from all participants in
the study.
MS-diagnosis was made according to the 2010 revised
McDonald criteria (9), NMOSD-diagnosis was made according
to the international consensus diagnostic criteria for NMOSD
2015 (10). All SLE patients fulfilled the 1997 ACR classification
criteria (11).
All MS and NMOSD patients were a stable phase of disease
with a minimum of 3 months since the last relapse and
last glucocorticoid pulse. We excluded patients if they had
additional autoimmune, infectious or malignant conditions. We
correlated the LDG percentage with clinical information such
as Expanded Disability Status Scale (EDSS) score, number of
relapses, treatment, and duration of disease as well as titers
for anti-MOG (myelin oligodendrocyte glycoprotein) and anti-
AQP-4 (aquaporin-4) antibodies.
PBMC Isolation, Staining, and Flow
Cytometry
We isolated the PBMC layer with density-gradient separation
of 10ml heparin-anticoagulated blood, using the Ficoll-Paque
PLUS gradient (GE Healthcare). PBMCs were washed once
in phosphate-buffered saline (PBS) supplemented with 3%
bovine serum albumin (BSA) and subsequently stained with
the following antibody-conjugates: CD45 FITC (Miltenyi
Biotec Cat# 130-080-202, RRID:AB_244234), CD14 Cy5
(DRFZ, clone TM1), CD15 PE-Cy7 (BioLegend Cat# 323029,
RRID:AB_2561669), CD16 PE (BioLegend Cat# 302008,
RRID:AB_314208), CD14 APC-Cy7 (BioLegend Cat# 367108,
RRID:AB_2566710), and CD11c Pacific Blue (BioLegend Cat#
337212, RRID:AB_1595430). We acquired the sample using
a FACSCanto (BD Biosciences) or MACSQuant (Miltenyi)
cytometer. For imaging flow cytometry (Amnis), we isolated and
stained the cells as described above, fixed the sample with the
Foxp3 / Transcription Factor Staining Buffer Set (eBioscience)
and acquired the cells on an Amnis ImageStream X Mark II.
All cytometry experiments were performed in accordance with
the “Guidelines for the use of flow cytometry and cell sorting in
immunological studies” (12).
FACS Data Analysis
We excluded sub-cell-sized detritus and doublets based on scatter
characteristics and gated on CD45+ leukocytes. Of these, we
defined LDGs as CD14−CD15high and calculated the ratio of
LDGs of all CD45+ PBMCs (Figure 1A).We then determined the
fraction of CD16high LDGs. FACS Data Analysis was performed
using FlowJo Version 10.4.1 (FlowJo LLC). We analyzed the
ImageStream data with IDEAS Version 6.2 (Amnis).
Statistical Analysis
The percentage of LDGs of different disease states and the
percentage of CD16high LDGs were compared to HDs using the
Kruskal-Wallis test with Dunn’s Correction for multiple testing.
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FIGURE 1 | (A) LDGs (CD14−CD15high) are a feature NMOSD and MS but not HDs (HD: n = 23, NMOSD: n = 20, MS: n = 17 SLE: n = 15). Bars indicate median
and 95% Confidence Intervals. The horizontal bar indicates 0.7%, a cut-off that separates all HDs from 17/20 NMOSD, 11/17MS samples as well as 13/15 SLE.
Kruskal-Wallis test with Dunn’s Correction for multiple testing **p < 0.005 and ****p < 0.0001. (B) Most LDGs are CD16high, but there are more CD16high LDGs in
NMOSD and MS than in HDs. There are some outliers with very low levels of CD16high LDGs. Bars indicate median and 95% Confidence Intervals. Kruskal-Wallis test
with Dunn’s Correction for multiple testing (HD: n = 23, NMOSD: n = 20, MS: n = 16 SLE: n = 15), test, *p < 0.05 and ***p < 0.001. (C) LDGs are CD11b+ [Gated
on CD14-CD15+, gray: fluorescence minus one (FMO) control].
For the difference between two groups, we used the Mann-
Whitney test. All statistical analysis was performed in GraphPad
Prism Version 7.0e for Mac OS X (GraphPad Software).
RESULTS
LDGs are a feature of many inflammatory conditions and of
unknown pathogenic significance. To elucidate whether LDGs
also exist in NMOSD and MS, we performed FACS analyses of
76 peripheral blood samples.
Cohort Description
We conducted the analysis of 17MS patients as well as 20
patients with NMOSD, of which 8 were anti-AQP4 positive and
4 positive for anti-MOG antibodies. Fifteen patients with SLE
and 23 HDs served as controls. Median EDSS scores were 4.0
in the MS and 3.0 in the NMOSD group. The most common
treatments in the MS group were dimethylfumarate (6/17) and
beta Interferon (4/17). The median number of relapses in the
relapse-remitting MS (RRMS) patients was 2.5. NMOSD Patients
were most often treated with Rituximab (8/20), Mycophenolate
(4/20), and azathioprine (4/20) (Table 1).
Low-Density Granulocytes Are a Feature of
Both Multiple Sclerosis and Neuromyelitis
Optica
In comparison to healthy controls, both MS and NMO patients
feature a significantly higher percentage of LDGs. SLE samples
displayed the highest frequencies of LDGs (MS: 0.9%, NMO
2.1%, SLE: 4.3%, HD: 0.2%, median fraction of CD45+ cells)
(Figure 1A). None of the HDs, but 17/20 NMOSD and 11/17MS
samples as well as 13/15 SLE samples had at least 0.7 %
LDGs. The fraction of CD16high LDGs differed both between
and within groups (Figure 1B), but was significantly higher in
NMOSD and MS compared to HCs. LDGs uniformly expressed
CD11b (Figure 1C).
LDGs Show a Heterogeneous Nuclear
Morphology
We analyzed the nuclear morphology of the LDGs of patients
withNMOSD,MS, and SLE.While some of the CD14−, CD15high
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TABLE 1 | Epidemiological information of the study population.
NMOSD (n = 20) MS (n = 17) HD (n = 23) SLE (n = 15)
Age (median and interquartile range) 48 (34.0–56.5) 47 (36.0–51.0) 29 (27.0–43.5) 40 (31.0–48.0)
Sex (n and percentage female) 17 (85.0) 5 (29.4) 15 (65.2) 14 (93.3)
Time since disease onset (in years,
median and interquartile range)
7.0 (3.0–8.8) 9.7 (4.6–15.4) – 13.0 (5.5–17.7)
Time since last relapse (in years,
median and interquartile range)
n.d. 3.4 (1.5–8.3) – n.d.
Clinical severity (EDSS for MS and
NMOSD, SLEDAI for SLE median and
interquartile range)
3 (1.5–4.5) 4 (2.0–5.0) – 5 (2.0 – 7.0)
Treatments (n, percentage) Rituximab n = 8 (40.0),
Azathioprine and untreated
each n = 4 (20.0),
Mycophenolate n = 3 (15.0),
Teriflunomide n = 1 (5.0)
Dimethylfumarat n = 6 (35.3),
Interferon beta n = 4 (23.4),
untreated n = 3 (17.6),
Daclizumab, intrathecal Steroids,
Glatirameracetate and
Fingolimod each n = 1 (5.9)
– Prednisolone n = 15 (100.0),
Hydroxychloroquine n = 7 (46.7),
Mycophenolate n = 3 (20.0),
Azathioprine, Methotrexate and
Cyclosporine A each n = 2
(13.3), Rituximab n = 1 (6.67)
Autoantibody Status (n, percentage) AQP-4 n = 8 (40.0)
MOG n = 4 (20.0)
– – –
% of LDGs (median and interquartile
range)
2.1 (1.1–4.1) 0.9 (0.57–1.63) 0.2 (0.2–0.4) 4.3 (1.0–9.5)
% of CD16high LDGs (median and
interquartile range)
91.2 (77.2–94.9) 87.8 (67.3–94.4) 65.6 (53.7–79.9) 84.6 (64.6–89.6)
n.d. no data.
FIGURE 2 | Imaging flow cytometry analysis of LDGs from a healthy donor and patients with SLE, MS, and NMOSD revealed LDGs with heterogenous nuclear
shapes, ranging from round to multisegmented.
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cells displayed the segmented nuclear shape typical of mature
granulocytes, others showed band-formed or rounded nuclei,
which are traditionally thought to be immature forms (Figure 2).
Untreated NMOSD Patients Show Higher
LDG Fractions
We looked for associations between the fraction of LDGs in
MS and NMOSD patients and their clinical characteristics
such as time since first manifestation of disease, number of
relapses, severity of disability as judged by the EDSS score,
type of treatment and antibody status, but did not find any
significant correlations (data not shown). NMOSD patients who
did not receive a continuous immunosuppressive treatment had
significantly higher LDG percentages compared to their peers
receiving treatment (median LDGs treated 1.4%, untreated 7.9%,
p < 0.01). The percentage of the LDG fraction did not correlate
with clinical severity, number of relapses or antibody status.
DISCUSSION
This study demonstrates the presence of Low-Density
Granulocytes in MS and NMOSD.
In contrast to MS, in NMOSD classical granulocytes are
thought to play a pivotal role as they can be found in tissue
biopsies (7) and alterations in neutrophil function have been
described (8). We recently described CD11b+ leucocytes in the
PBMCs of MS patients that were characterized by increased
activation of NAD(P)H oxidase (NOX) (13). In these, NOX
activation correlated with clinical activity. While we assumed
these cells to be monocytes at the time, the presence of LDGs
in the peripheral blood mononuclear cell (PBMC) fraction could
pose an alternative explanation for our previous results.
We found the LDG fraction of NMOSD and MS patients to
contain significantly more CD16high cells, a marker indicating
neutrophil maturity. As previously described for LDGs in SLE,
LDG nuclei in NMOSD vary between mature segmented and
immature round forms. In previous studies, the immature
nuclear morphology was associated with an expression of surface
markers characteristic of mature cells, suggesting that LDGs do
not fit into the traditional maturity spectrum of granulocytes (6).
This work adds MS and NMOSD to the diverse list of
inflammatory conditions featuring LDGs. In our opinion,
this makes it more likely that LDGs are an epiphenomenon
of ongoing inflammation rather than a causal part of the
pathogenesis of a specific disease, but further research is needed
to establish the role of these cells in different conditions.
Interestingly, NMOSD patients often have additional immune-
mediated disorders, especially SLE (14). The fact that these
disorders both show high fractions of LDGs could also
point toward shared pathogenetic mechanisms. A recent study
reported a strong correlation of LDGs and glucocorticoid use
in large transcriptional data sets of SLE patients (15). This is
in contrast to our results, as none of the MS and NMOSD
patients received systemic glucocorticoid treatment in the last
3 months.
To establish the potential of LDGs as a biomarker in
neuroinflammatory diseases or inflammation in general, analysis
of larger and longitudinal cohorts should be performed to
uncover potential correlations with disease severity or prognosis.
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